IRIS
BIANCHINI, GIAMPAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.721
EU - Europa 3.449
AS - Asia 2.867
SA - Sud America 459
Continente sconosciuto - Info sul continente non disponibili 390
AF - Africa 47
AN - Antartide 1
OC - Oceania 1
Totale 10.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.439
RU - Federazione Russa 1.741
IT - Italia 1.057
SG - Singapore 1.048
CN - Cina 949
BR - Brasile 366
HK - Hong Kong 337
VN - Vietnam 221
CA - Canada 147
FR - Francia 136
DE - Germania 128
BD - Bangladesh 118
GB - Regno Unito 109
NL - Olanda 75
FI - Finlandia 59
IN - India 48
MX - Messico 36
AR - Argentina 32
CR - Costa Rica 30
PL - Polonia 29
JP - Giappone 27
CO - Colombia 23
AT - Austria 22
ES - Italia 20
ZA - Sudafrica 18
SE - Svezia 17
ID - Indonesia 15
EC - Ecuador 14
PK - Pakistan 14
IQ - Iraq 13
JM - Giamaica 13
TR - Turchia 12
MY - Malesia 10
NI - Nicaragua 10
TT - Trinidad e Tobago 9
GT - Guatemala 8
IE - Irlanda 8
NP - Nepal 8
UA - Ucraina 8
VE - Venezuela 8
EE - Estonia 7
HN - Honduras 7
PY - Paraguay 6
SV - El Salvador 6
TN - Tunisia 6
UZ - Uzbekistan 6
HU - Ungheria 5
LT - Lituania 5
PH - Filippine 5
AE - Emirati Arabi Uniti 4
DK - Danimarca 4
KE - Kenya 4
KR - Corea 4
PR - Porto Rico 4
RO - Romania 4
SA - Arabia Saudita 4
BE - Belgio 3
CL - Cile 3
DZ - Algeria 3
EG - Egitto 3
GE - Georgia 3
JO - Giordania 3
PE - Perù 3
TH - Thailandia 3
AL - Albania 2
AZ - Azerbaigian 2
BB - Barbados 2
BS - Bahamas 2
CW - ???statistics.table.value.countryCode.CW??? 2
IL - Israele 2
KG - Kirghizistan 2
MD - Moldavia 2
OM - Oman 2
SC - Seychelles 2
TW - Taiwan 2
UG - Uganda 2
UY - Uruguay 2
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BF - Burkina Faso 1
BO - Bolivia 1
BY - Bielorussia 1
BZ - Belize 1
CG - Congo 1
CH - Svizzera 1
CI - Costa d'Avorio 1
CU - Cuba 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
GD - Grenada 1
GH - Ghana 1
GP - Guadalupe 1
GY - Guiana 1
HR - Croazia 1
HT - Haiti 1
KW - Kuwait 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
Totale 10.536
Salva come PNG Salva come JPEG
Città #
Singapore 558
Ashburn 465
San Jose 441
Moscow 379
Hong Kong 330
Council Bluffs 216
Milan 211
Dallas 197
Shanghai 151
Phoenix 143
Beijing 122
Rome 111
New York 108
Hefei 106
Santa Clara 92
Lauterbourg 88
Ho Chi Minh City 85
Los Angeles 80
Hanoi 55
Boardman 51
São Paulo 40
Chicago 39
Nuremberg 39
Orem 39
Montreal 36
Naples 34
Atlanta 28
Lappeenranta 25
Warsaw 25
Mexico City 24
North Bergen 24
Brooklyn 23
Florence 23
Guangzhou 23
Helsinki 23
Turin 22
Boston 21
Brescia 21
London 21
Miano 21
San José 21
Philadelphia 20
Toronto 19
Manchester 18
Tokyo 17
Houston 16
Munich 16
Genoa 15
Shenzhen 15
Washington 15
Bologna 14
Buffalo 14
Cesano Boscone 14
Denver 14
Poplar 14
Bari 13
Brasília 12
Falkenstein 12
Johannesburg 12
Miami 12
Calgary 11
Chennai 11
Las Vegas 11
Princeton 11
Queens 11
Rio de Janeiro 11
Charlotte 10
Curitiba 10
Managua 10
San Francisco 10
Venice 10
Kingston 9
Paris 9
Seattle 9
Stockholm 9
The Bronx 9
Amsterdam 8
Assago 8
Campinas 8
Frankfurt am Main 8
Lahore 8
Ottawa 8
Pittsburgh 8
Vienna 8
Belo Horizonte 7
Bogotá 7
Dhaka 7
Guatemala City 7
Hangzhou 7
Lawrence 7
New Delhi 7
Palermo 7
Turku 7
Wolfhagen 7
Baghdad 6
Charleston 6
Cincinnati 6
Dublin 6
Jacksonville 6
Jiaxing 6
Totale 5.174
Salva come PNG Salva come JPEG
Nome #
Spatial predictors of immunotherapy response in triple-negative breast cancer 214
Management of Trastuzumab Deruxtecan-related nausea and vomiting in real-world practice 193
Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment 161
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial 160
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial 151
Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study 146
Tissue- and liquid biopsy-based biomarkers for immunotherapy in breast cancer 141
Definition of High-Risk Early Hormone-Positive HER2−Negative Breast Cancer: A Consensus Review 131
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer 131
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis 129
Completion Rate and Positive Results Reporting among Immunotherapy Trials in Breast Cancer, 2004-2023 129
Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial 129
Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy 124
Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response 123
Timing of Recurrence after Neoadjuvant Chemo-Immunotherapy in Patients with Early-Stage Triple-Negative Breast Cancer 118
PARP Inhibitors for Breast Cancer Treatment: A Review 115
[18F]FDG PET/MRI vs sentinel node biopsy for axillary staging of early breast cancer patients. A prospective single-arm trial 112
Modulation of the estrogen/erbB2 receptors crosstalk by CDK4/6 inhibition triggers sustained senescence in estrogen receptor and erbB2 positive breast cancer 111
Treatment landscape of triple-negative breast cancer — expanded options, evolving needs 110
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial 108
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treatm. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 106
Dermatological and Dermoscopic Baselines in BRCA Mutation Carriers 106
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working Group 104
Immunotherapy for early triple negative breast cancer: research agenda for the next decade 104
A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. 104
ASTEFANIA: adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer 103
Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen 103
Pet/mri for staging the axilla in breast cancer: Current evidence and the rationale for snb vs. pet/mri trials 100
Real-world effectiveness comparison of first-line palbociclib, ribociclib or abemaciclib plus endocrine therapy in advanced HR-positive/HER2-negative BC patients: results from the multicenter PALMARES-2 study 98
Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs) 96
Accurate data processing improves the reliability of Affymetrix gene expression profiles from FFPE samples. 96
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial 95
Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication 94
BREAST CANCER GENOMICS: CHALLENGES IN INTERPRETATION AND APPLICATION 94
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancer 93
Primary Founder Mutations in the PRKDC Gene Increase Tumor Mutation Load in Colorectal Cancer 93
Real-world use of multigene signatures in early breast cancer: differences to clinical trials 91
Assessing cost-utility of predictive biomarkers in oncology: a streamlined approach. 91
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancer 90
Controversial topics in metastatic HR+/HER2- breast cancer: Guiding treatment by a modified Delphi approach 89
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer? 87
Corrigendum to “Breaking barriers in triple negative breast cancer (TNBC) – Unleashing the power of antibody-drug conjugates (ADCs)” [Cancer Treatment Reviews 123 (2024) 102672] (Cancer Treatment Reviews (2024) 123, (S0305737223001652), (10.1016/j.ctrv.2023.102672)) 85
Correction: Extracellular matrix/integrin signaling promotes resistance to combined inhibition of HER2 and PI3K in HER2 þ breast cancer 85
An unmet need: tailoring extended adjuvant endocrine therapy. 85
BIOLOGICAL PROCESSES ASSOCIATED WITH PROGNOSIS AND CHEMOTHERAPY SENSITIVITY IN MOLECULAR SUBTYPES OF BREAST CANCER 84
Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer 83
Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives 81
Emetogenicity of Antibody-Drug Conjugates (ADCs) in Solid Tumors with a Focus on Trastuzumab Deruxtecan: Insights from an Italian Expert Panel 81
Association Between Genomic Metrics and Immune Infiltration in Triple-Negative Breast Cancer 81
Comparison of tumor-infiltrating lymphocytes between primary and metastatic tumors in breast cancer patients 81
Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial 81
Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer 78
Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab 78
Association between red and processed meat consumption and colorectal cancer risk: a comprehensive meta-analysis of prospective studies 77
Tucatinib's journey from clinical development to clinical practice: New horizons for HER2-positive metastatic disease and promising prospects for brain metastatic spread 76
Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers 76
Corrigendum to “Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review” [Cancer Treat. Rev. 114 (2023) 102511] (Cancer Treatment Reviews (2023) 114, (S0305737223000026), (10.1016/j.ctrv.2023.102511)) 75
IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer 74
Optimizing choices and sequences in the diagnostic-therapeutic landscape of advanced triple-negative breast cancer: An Italian consensus paper and critical review 74
Prognostic significance of a signature based on senescence-related genes in colorectal cancer 74
Impact of molecular subtype on 1325 early-stage breast cancer patients homogeneously treated with hypofractionated radiotherapy without boost: Should the indications for radiotherapy be more personalized? 74
Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice 72
Somatostatin response to a mixed meal in normals and in type I diabetics 72
Neoadjuvant immunotherapy in triple-negative breast cancer: lesson learnt, remaining questions 72
Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer 71
NEW STRATEGIES IN BREAST CANCER: IMMUNOTHERAPY 71
Personalized Risk–Benefit Ratio Adaptation of Breast Cancer Care at the Epicenter of COVID-19 Outbreak 69
PCSK9 expression and cancer survival: a prognostic biomarker at the intersection of oncology and geroscience 68
Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies 68
The TRAR gene classifier to predict response to neoadjuvant therapy in HER2-positive and ER-positive breast cancer patients: an explorative analysis from the NeoSphere trial 68
Immunological differences between primary and metastatic breast cancer 68
Navigating practical challenges in immunotherapy for metastatic triple negative breast cancer 66
Determinants of response and molecular dynamics in HER2+ER+ breast cancers from the NA-PHER2 trial receiving HER2-targeted and endocrine therapies 66
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease 65
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer. 65
How I treat HER2-positive early breast cancer: how long adjuvant trastuzumab is needed? 64
First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. 63
Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer 62
Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation. 61
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma 61
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus report 60
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. 60
Is trastuzumab as a single agent obsolete in early breast cancer? No 59
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer after Progression on CDK4/6 Inhibition: Results from the Phase III postMONARCH Trial 59
Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers. 58
Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. 57
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer 57
Breastfeeding after breast cancer in young BRCA carriers 56
Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. 56
Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients 56
Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. 55
Dissecting time- from tumor-related gene expression variability in bilateral breast cancer 55
Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group 55
Comparative analysis of Denosumab and Zoledronic acid in advanced breast cancer patients receiving CDK4/6 inhibitors 54
Immune Gene Expression Is Associated with Genomic Aberrations in Breast Cancer 54
Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer 53
Treatment options in hormone-refractory metastatic prostate carcinoma. 53
DNA REPAIR GENE PATTERNS AS PROGNOSTIC AND PREDICTIVE FACTORS IN MOLECULAR BREAST CANCER SUBTYPES 53
Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care 53
Introducing new molecular technologies into routine clinical cancer care: Is there an impact on the treatment of breast cancer? 52
Totale 8.743
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.449
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.449
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20224 0 0 0 0 0 0 0 2 1 1 0 0
2022/202322 11 4 1 0 0 2 0 1 0 0 0 3
2023/2024204 0 0 3 3 1 42 12 8 1 3 60 71
2024/20251.778 239 82 15 96 164 150 287 214 232 96 91 112
2025/20266.041 352 387 271 650 456 206 588 446 1.772 395 223 295
2026/20272.884 288 705 674 1.217 0 0 0 0 0 0 0 0
Totale 10.935